Podcasts about Moderna

This 'Media Buzz Meter' first aired on February 19th, 2026… Howie Kurtz on Former Prince Andrew being arrested on allegations of sharing UK trade secrets with Jeffrey Epstein, the partial government shutdown impacting FEMA's disaster recovery efforts, and the FDA's decision to review Moderna's application for an mRNA-based flu vaccine. Learn more about your ad choices. Visit podcastchoices.com/adchoices

In "Somebody to Lean On," Dr. Osterholm and Chris Dall discuss vaccine updates including the FDA's back-and-forth on the Moderna vaccine, leadership shake-ups at institutions like the CDC, and the current state of measles in the US. Dr. Osterholm will also bring you a respiratory virus update, including current vaccine guidance for flu, COVID and RSV. Op-Ed: The FDA refused to review a flu vaccine, contrary to evidence. Now the agency reversed itself (CIDRAP) The State of US Vaccine Policy (CIDRAP and Unbiased Science)Dentists still write millions of prescriptions a year for an antibiotic with life-threatening risks (CIDRAP)  Resources for vaccine and public health advocacy: Voices for Vaccines Families Fighting Flu Vaccinate Your Family Shot@Life Medical Reserve Corps Learn more about the Vaccine Integrity Project MORE EPISODES       SUPPORT THIS PODCAST   Music: "Beauty Flow" Kevin MacLeod (incompetech.com)Licensed under Creative Commons: By Attribution 4.0 License

We're marking Rare Disease Month 2026 by highlighting the powerful story of Shanthi Hegde, a young patient advocate working to transform how bleeding disorders are understood, treated, and supported. This work is fueled by her own arduous journey with two rare bleeding disorders and immune dysregulatory syndrome, and an extended diagnostic odyssey marked by dismissal, underdiagnosis, and structural bias. “I was told many times by many providers that these disorders are not common in Indians and that my bruises were there just because I'm brown.” Admirably, Shanthi pushed past this mistreatment, advocated for her medical needs, and devoted herself to tackling a range of issues confronting rare disease patients from mental health access to affordable drug pricing to research equity. In this remarkable Year of the Zebra conversation with host Lindsey Smith, you'll also learn about: Shanti's work with the Hemophilia Federation of America; How gaps extend beyond treatment to include insurance coverage, provider training, and substance use care; What clinicians can do to improve the work they do with rare disease patients. Join us for a conversation that connects patient voice to system change, and explores what real equity for rare disease communities will require. Mentioned in this episode:Hemophilia Federation of AmericaShanthi's LinkedIn Profile If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

American officials say they believe China held a nuclear test in 2020, and President Trump reserves the right to do the same, as the New Start arms-control treaty with Russia hits its expiration date this month. Plus, the Food and Drug Administration summarily rejects a flu vaccine from Moderna, before changing course. Learn more about your ad choices. Visit megaphone.fm/adchoices

Gilead is acquiring Arcellx for $7.8 billion up front three years after forging a partnership with the biotech around a cell therapy for multiple myeloma. On the latest BioCentury This Week podcast, BioCentury's analysts assess what the deal does for the Foster City, Calif.-based biotech's pipeline.The analysts also discuss the case for using ctDNA as a surrogate endpoint for early cancer trials. Turning to Washington, Steve Usdin offers his takeaways from last week's PhRMA Forum, which focused on China and the Trump administration's most favored nation (MFN) drug pricing policy, and on the lessons that can be drawn from FDA's about-face on the recent vaccine application from Moderna.View full story: https://www.biocentury.com/article/658516#BiotechMA #MultipleMyeloma #ctDNA #DrugPricingPolicy #FDA00:00 - Introduction02:34 - Gilead's Arcellx Buy11:14 - ctDNA Surrogate Endpoints21:59 - PhRMA Forum Takeaways29:19 - FDA Moderna U-turnTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

La politique antivaccins des Etats-Unis ne lui facilite pas la tâche. Depuis la fin de la pandémie, la biotech américaine Moderna perd de l'argent. Elle s'est peu renouvelée depuis qu'elle a vendu au monde entier son vaccin contre le Covid. Dans «La Story», le podcast d'actualité des «Echos», Clara Grouzis et Myriam Chauvot racontent les déboires de cette entreprise.« La Story » est un podcast des « Echos » présenté par Clara Grouzis. Cet épisode a été enregistré en février 2026. Rédaction en chef : Clémence Lemaistre. Invitée : Myriam Chauvot (journaliste aux Echos spécialiste de la santé). Réalisation : Willy Ganne. Chargée de production et d'édition : Clara Grouzis. Musique : Théo Boulenger. Identité graphique : Upian. Photo : AdobeStock. Sons : Arte, RMC, RTBF, Washington Post.Retrouvez l'essentiel de l'actualité économique grâce à notre offre d'abonnement Access : abonnement.lesechos.fr Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Barbara_O'Neill

Gregory Zuckerman describes the climactic moment vaccine results arrived, with Pfizer and Moderna reporting high efficacy, while Novavax and AstraZeneca faced unique logistical and reputational challenges. 7

Gregory Zuckerman highlights Moderna's desperate struggle for funding and manufacturing equipment, which was finally resolved by a massive Wall Street investment during the pandemic's peak. 5

Why did Walmart fall on strong earnings? And how are Omnicom's big cost cuts boosting its stock? Plus, will a major FDA reversal change Moderna's fortunes? Host Jack Pitcher discusses the biggest stock moves of the week and the news that drove them.Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Why did Walmart fall on strong earnings? And how are Omnicom's big cost cuts boosting its stock? Plus, will a major FDA reversal change Moderna's fortunes? Host Jack Pitcher discusses the biggest stock moves of the week and the news that drove them.Sign up for the WSJ's free Markets A.M. newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

The Food and Drug Administration will review Moderna's new flu vaccine after reversing course. Medicare Advantage growth in 2026 is trailing prior years. And Amazon is expanding same-day prescription delivery to nearly 5,000 cities nationwide. Those stories and more on today's episode of The Gist Healthcare Podcast. Hosted on Acast. See acast.com/privacy for more information.

TODAY ON THE ROBERT SCOTT BELL SHOW: Jonathan Emord, Pharma Attacks RFK Jr., FDA Moderna Reversal, MAHA Midterm Strategy, Voter ID, Hawaii's Emergency Power Grab, Ari Whitten, Red Light Therapy, Inflammation Reduction, Anhalonium Lewinii, and MORE! https://robertscottbell.com/jonathan-emord-pharma-funded-attacks-on-rfk-jr-fdas-moderna-reversal-maha-midterm-strategy-voter-id-hawaiis-emergency-power-grab-anhalonium-lewinii-and-more/ Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

Pink Sheet Executive Editor Derrick Gingery, Managing Editor Bridget Silverman, Senior Editor Sue Sutter, and Editor-in-Chief Nielsen Hobbs discuss a series of US Food and Drug Administration proposals for user fee program changes that would advance President Trump's priorities and the concerns they raise (:31). They also consider the impact of the agency's decision to review Moderna's mRNA flu vaccine application shortly after refusing to file it and using accelerated approval for one of the proposed indications (8:37), as well as ideas for sponsors wondering if their development advice is still good (25:24). More On These Topics From The Pink Sheet US FDA Proposing White House-Aligned Policies For User Fee Agreements: https://insights.citeline.com/pink-sheet/pathways-and-standards/user-fees/us-fda-proposing-white-house-aligned-policies-for-user-fee-agreements-D5JWRDGLCFBT7CYT3FGK3JAZNI/ After Moderna Flu Vaccine, Is US FDA's Accelerated Approval A Pathway Or A Pressure Valve?: https://insights.citeline.com/pink-sheet/pathways-and-standards/review-pathways/after-moderna-flu-vaccine-is-us-fdas-accelerated-approval-a-pathway-or-a-pressure-valve-EWMFKFWO3BB3JA6CQHC4E3JWPA/ Moderna Flu Vaccine Debate Could Resolve With Postmarket Study, FDA's Makary Suggests: https://insights.citeline.com/pink-sheet/vaccines/moderna-flu-vaccine-debate-could-resolve-with-postmarket-study-makary-suggests-Y3R657N2JZABRGFOSKADM33YA4/ Horse Trading? Oz, Bourla Exchange MFN Codification, Vaccine Collaboration Requests: https://insights.citeline.com/pink-sheet/market-access/pricing-debate/horse-trading-oz-bourla-exchange-mfn-codification-vaccine-collaboration-requests-X6UDDVOSMRBSTO5WC224IN6PTE/

On this week's episode, Eric Schmidt, Paul Matteis, Sam Fazeli, Graig Suvannavejh, and Luba Greenwood kick off with a discussion on the surge in out licensing deals and growing drug development momentum in China -- a trend they expect will continue. The conversation then shifts to market sentiment, touching on biotech outlook and M&A. in policy news, the group highlights that the FDA reversed its refusal to file a letter for Moderna's flu vaccine after President Trump met with Dr. Marty Makary. They also discuss the FDA's recent regulatory unpredictability, particularly in vaccines and rare diseases. Next, the co-hosts highlight Denali Therapeutics' upcoming PDUFA date for its Hunter syndrome therapy as another test of the FDA's flexibility. The group notes the agency's paper published in NEJM announcing approval of certain drugs based on a single clinical trial, with some viewing it positively for biotech innovation while others caution it may be meaningless, especially with leadership changes. The co-hosts close the discussion on regulatory news by reflecting on positives that have emerged during the Dr. Makary/Dr. Prasad era. In company news, the co-hosts discuss an analysis on the Keytruda patent landscape J&J's investment in a new cell therapy manufacturing plant and data updates from Roche in kidney disease and Compass Pathways' latest psilocybin results. *This episode aired on February 20, 2026.

The Trump administration appears to be gearing up for a substantial response to Iran, Washington State allegedly spends millions on gender surgeries for inmates, and whiplash hits Moderna as the FDA reverses its decision to not review the company's new flu vaccine. Get the facts first with Morning Wire.- - -Ep. 2640- - -Wake up with new Morning Wire merch: https://bit.ly/4lIubt3- - -Today's Sponsors:Hello Fresh - Go to https://HelloFresh.com/morningwire10fm to Get 10 free meals + a FREE Zwilling Knife (a $144.99 value) on your third box. Offer valid while supplies last.Vanta - Get started at https://Vanta.com/MORNINGWIRE- - -Privacy Policy: https://www.dailywire.com/privacymorning wire,morning wire podcast,the morning wire podcast,Georgia Howe,John Bickley,daily wire podcast,podcast,news podcast Learn more about your ad choices. Visit podcastchoices.com/adchoices

The twists and turns continue at the nation's health agency, where this week's announcements included notice that the Food and Drug Administration will review Moderna's new flu vaccine after all and that a handful of top agency officials are getting new jobs.Those developments and others can be traced to a White House looking to shake things up before the midterms — and win over voters on health care. Tami Luhby of CNN, Shefali Luthra of The 19th, and Lauren Weber of The Washington Post join KFF Health News' Mary Agnes Carey to discuss these stories and more. Visit our website for a transcript of this episode.Plus, for “extra credit” the panelists suggest health policy stories they read this week that they think you should read, too:  Mary Agnes Carey: Politico's “Why Congress Failed To Reach an Obamacare Deal,” by Robert King and Simon J. Levien. Lauren Weber: NiemanLab's “The Atlantic's Elizabeth Bruenig on Her ‘Hypothetical,' Heavily Reported Measles Essay,” by Laura Hazard Owen. Tami Luhby: The City's “NewYork-Presbyterian Nurses Reject Contract by Overwhelming Margin,” by Claudia Irizarry Aponte and Ben Fractenberg. Shefali Luthra: NPR's “Minneapolis Doctors Warn of Lasting Medical Effects, Even After ICE Agents Leave,” by Jasmine Garsd. 

Howie Kurtz on Former Prince Andrew being arrested on allegations of sharing UK trade secrets with Jeffrey Epstein, the partial government shutdown impacting FEMA's disaster recovery efforts, and the FDA's decision to review Moderna's application for an mRNA-based flu vaccine. Learn more about your ad choices. Visit podcastchoices.com/adchoices

This week on The Health Advocates, we unpack a series of developments that signal a pivotal moment in U.S. health policy. The FDA has refused to review Moderna’s new mRNA-based flu vaccine, raising questions about regulatory standards and the future of vaccine innovation. At the same time, the Trump administration has launched TrumpRx, a new prescription drug discount platform that promises savings but faces scrutiny over its scope and real-world impact.We also examine new polling showing declining confidence in flu, COVID-19, and MMR vaccines, and the growing legal battle over changes to the federal childhood vaccine schedule. With public trust, regulatory rigor, and patient access all in play, this episode breaks down what these headlines mean for patients — and why clarity and credible science matter more than ever. Contact Our HostSteven Newmark, Chief of Policy at GHLF: snewmark@ghlf.orgA podcast episode produced by Ben Blanc, Director, Digital Production and Engagement at GHLF.We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to podcasts@ghlf.orgListen to all episodes of The Health Advocates on our website or on your favorite podcast channel.See omnystudio.com/listener for privacy information.

Few issues have tested public trust in medicine as deeply as vaccines, and few individuals have influenced that dialogue more than Dr. Paul Offit, director of the Vaccine Education Center at the Children's Hospital of Philadelphia and a longtime member of the FDA's Vaccine Advisory Committee. In this timely and candid interview with Raise the Line host Lindsey Smith, Dr. Offit points to this year's severe flu season and a resurgence of measles as alarming proof points of how a changing federal perspective on vaccine policy is having a real impact on public health. “You'd like to think you can educate about the importance of vaccines, but I fear at this point the viruses themselves are doing the educating.” In this wide ranging discussion, Dr. Offit also addresses: The rigorous and painstaking process of developing vaccines, based on his experience co-inventing the rotavirus vaccine. Shifting levels of public trust in scientific organizations. Promising innovations in vaccine development. Don't miss this deeply-informed perspective on the interplay of science, policy, and public education, and his encouraging message to young clinicians about managing the current challenges in public health.  Mentioned in this episode: Vaccine Education Center at Children's Hospital of PhiladelphiaPerelman School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Jonathan and Wendy unpack how culture war politics, anti-vaccine ideology, and regulatory power are colliding in dangerous ways. The conversation begins with criticism Jonathan received after arguing that trans healthcare decisions should be left to doctors, patients, and families—not debated for podcast content or political gain. The discussion then pivots to the measles resurgence, including outbreaks in ICE detention centers and efforts to minimize measles deaths using recycled COVID-era talking points. They examine five recurring myths being repurposed from COVID to measles: people are dying "with" not "of" the disease, only sick children die, the outbreak is "almost over," vaccines are more dangerous than the illness, and doctors are to blame for deaths. Finally, they analyze the FDA's controversial refusal to review Moderna's mRNA flu vaccine, exploring what that decision signals about regulatory instability, innovation suppression, and long-term damage to vaccine research in the U.S. Connect with us further on https://sciencebasedmedicine.org/author/jonathanhoward/  The Fine Print The content presented in the "We Want Them Infected" Podcast and associated book is intended for informational and educational purposes only.    The views and opinions expressed by the speakers, hosts, and guests on the podcast do not necessarily reflect the views of the creators, producers, or distributors. The information provided in this podcast should not be considered as a substitute for professional medical, scientific, or legal advice. Listeners and readers are encouraged to consult with relevant experts and authorities for specific guidance and information.   The creators of the podcast and book have made reasonable efforts to ensure that the information provided is accurate and up to date. However, as the field of medical science and the understanding of the COVID-19 pandemic continue to evolve, there may be new developments and insights that are not covered in this content.   The creators are not responsible for any errors or omissions in the content or for any actions taken based on the information provided. They disclaim any liability for any loss, injury, or damage incurred by individuals who rely on the content.   Listeners and readers are urged to use their judgment and conduct their own research when interpreting the information presented in the "We Want Them Infected" podcast and book. It is essential to stay informed about the latest updates, guidelines, and recommendations related to COVID-19 and vaccination from reputable sources, such as government health agencies and medical professionals. By accessing and using the content, you acknowledge and accept the terms of this disclaimer.   Please consult with appropriate experts and authorities for specific guidance on matters related to health, science, and the COVID-19 pandemic.  

Use o cupom LUTZ e Desbloqueie 20% OFF novos clientes | 10% OFF recorrentes, que soma com os descontos do site! #insiderstoreAcesse: https://creators.insiderstore.com.br/LUTZNilton Cáceres realiza pesquisas principalmente nas áreas de Ciências Ambientais, Ciências da Terra e Planetárias. O trabalho dele abrange diversas subáreas, incluindo: Ecologia, Paleontologia, Ecologia, Evolução, Comportamento e Sistemática, Conservação da Natureza e da Paisagem, Modelagem Ecológica.AS MELHORES PARTES DOS PODCASTS: Cortes do Lutz: https://www.youtube.com/@CortesdoLutzOFICIAL/LINKS DO EPISÓDIO:Insta do Nilton: https://www.instagram.com/nilton.caceresPUBLICIDADE:Entre em contato: comercial@lutzpodcast.comREDES SOCIAIS:Instagram do Lutz: https://instagram.com/lutzloboInstagram do Podcast: https://instagram.com/lutzpodcast

The U.N. says that Epstein's abuses may constitute 'crimes against humanity,' Vladimir Putin calls new U.S. restrictions on Cuba unacceptable, France and Algeria resume security cooperation, Israel's Bezalel Smotrich says that Israel will "encourage migration" of Palestinians from the West Bank and Gaza, Sara Duterte announces her 2028 Presidential bid in the Philippines, Beijing denies U.S. claims of nuclear tests in China, U.S. Department of Homeland Security spokesperson Tricia McLaughlin quits, Health and environmental groups sue the EPA over the rollback of emission standards, The FDA reverses its decision and will review Moderna's mRNA flu vaccine, and a new study warns that the Chikungunya virus could spread across Europe. Sources: Verity.News

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a wide array of topics, from groundbreaking therapies and strategic corporate moves to regulatory shifts and industry trends shaping the future of healthcare.We begin with Eli Lilly, which is making significant strides with its combined Zepbound and Taltz therapy, showing promising results in the treatment of psoriasis and obesity. This combination therapy, initially successful in psoriatic arthritis, is set to transform treatment protocols by bridging gaps between psoriasis and obesity. This dual-targeting approach highlights a burgeoning trend in the industry: the use of combination therapies to enhance patient outcomes while streamlining treatment regimens. This strategy not only promises better management of interconnected conditions but also reflects a broader industry goal of maximizing therapeutic reach with existing drugs.Novartis is advancing its portfolio with the oral BTK inhibitor, Rhapsido, following a successful Phase 3 trial for a new chronic hives subtype. This development underscores Novartis's commitment to addressing niche markets and unmet medical needs, emphasizing the pharmaceutical industry's focus on expanding the utility of existing drugs. Additionally, Novartis has entered into a notable partnership with Macrocycle Biotech for cardiovascular drug development. This collaboration represents a broader trend where large pharmaceutical companies seek innovative partnerships to expand their therapeutic portfolios through cutting-edge biotech solutions.Meanwhile, Moderna's influenza vaccine submission has been accepted by the FDA after an initial rejection, illustrating a responsive regulatory environment crucial for timely access to vaccines amid potential flu outbreaks.Johnson & Johnson's $1 billion investment plan in the U.S., focusing on cell therapy, aligns with broader industry trends towards personalized medicine and advanced therapeutic approaches. This investment is part of a strategic pivot towards cell and gene therapies that promise to redefine treatment pathways for complex diseases. Similarly, Bayer's $7.25 billion settlement over Roundup litigation shows an industry keen on resolving legal challenges swiftly to refocus efforts on innovation.Regulatory reforms are also gaining attention, with proposals aimed at streamlining FDA processes to enhance drug access and reduce burdens. These reforms could significantly impact drug development timelines and market entry strategies, reflecting an ongoing discourse on balancing regulation with fostering innovation.On a global scale, Stada's €85 million investment in Saudi Arabia points to a strategic move towards enhancing supply chain resilience in the Middle East and North Africa. This aligns with industry trends focusing on regional manufacturing capabilities to ensure drug availability while reducing logistical complexities.A notable example of strategic resource allocation is Eli Lilly's $100 million upfront payment for CSL's IL-6 antibody development rights. This reflects an adaptive approach where initial clinical setbacks are seen as opportunities for new therapeutic ventures rather than dead ends.Turning our attention to Alzheimer's research, Korsana Biosciences has emerged from stealth mode with substantial funding aimed at developing an anti-amyloid antibody capable of crossing the blood-brain barrier. This effort addresses a critical need within Alzheimer's disease treatment—a field marked by intense competition and scientific challenge. Parallelly, IQVIA Biotech highlights the importance of accelerating early-stage interventions for Alzheimer's through data analytics and optimized clinical trials. Such efforts aim to expedite regulatory approvals and bring new therapies to market faster—a trend indicative of leveragSupport the show

The FDA is agreeing to review Moderna's influenza vaccine. Officials defended the initial decision, saying the company should have given a higher-strength vaccine to older patients in the control arm of its trial. However, Moderna made revisions to its approach and is now seeking full approval for the shot for adults between 50 and 64 years old as well as accelerated approval for those aged 65 and above. We talked about this with Dr. Browne of Griffin Health.Image Courtesy of Griffin Health and Dr. Fred Browne

Är det livsfarligt att åka in i Bermudatriangeln? Finns det gigantiska snömän i Tibet? Existerar Nessie och Storsjöodjuret? Sover det ett lermonster – en golem – på vinden i en synagoga i Prag? Har utomjordingar verkligen landat i Roswell och Ängelholm?Frågorna är många. Och även om de flesta av oss avfärdar berättelserna som fantasifulla myter, fortsätter de att väcka fascination, spekulationer och nya teorier.När vi granskar dessa myter närmare visar det sig att de påfallande ofta är av mycket sent datum. Ett talande exempel är föreställningen om fredagen den 13 som en olycksdag. Enligt en seglivad berättelse går kopplingen tillbaka till Jesu sista måltid, där Judas Iskariot var den trettonde vid bordet – vilket i sin tur skulle ha lett till korsfästelsen på långfredagen. Men faktum är att ingen betraktade fredagen den 13 som otursförföljd före andra hälften av 1800-talet. Den verkliga explosionsartade spridningen av myten skedde först på 1900-talet.Samma sak gäller det berömda Loch Ness-odjuret. Den skotska turistindustrin påstår gärna att observationer av monstret går tillbaka till 500-talet. Men när vi undersöker källorna noggrant visar det sig att intresset för "Nessie" tog fart först på 1930-talet, då massmedier började rapportera om märkliga iakttagelser i sjön.I detta avsnitt av podden Harrisons dramatiska historia samtalar Dick Harrison, professor i historia vid Lunds universitet, med fackboksförfattaren Katarina Harrison Lindbergh om moderna myter – fascinerande föreställningar som ofta tas för sanningar, men som i själva verket uppstått först i modern tid.Bildtext: Golem och rabbi Löw avbildad på Madame Tussauds i Prag. Golem är en central gestalt i centraleuropeisk judisk mystik och folklore, ofta kopplad till 1500-talets Prag. Legenden belyser teman som skaparkraft, ansvar och gränsen mellan mänskligt och gudomligt. Foto: Edelmauswaldgeist – Eget arbete, licens: CC BY-SA 4.0.Klippare: Emanuel Lehtonen Hosted on Acast. See acast.com/privacy for more information.

One legend exits, a streaming war reignites, and AI redraws the market map - where should investors focus now? In this episode, hosted by Michelle Martin with Ryan Huang, we unpack Warren Buffett’s last portfolio reshuffle at Berkshire Hathaway - trimming Apple, Amazon and Bank of America while adding some well-known names. Berkshire has now been a net seller for 13 straight quarters - is the Oracle signalling caution at peak valuations? In media, Warner Bros Discovery’s $70B content deal with Netflix faces a last-minute push from Paramount - can it outbid and reshape the streaming battlefield? Tech leads markets higher as Nvidia inks a multi-year AI infrastructure deal with Meta, potentially squeezing Broadcom’s edge. In UP or DOWN, we size up Palo Alto Networks’ profit miss, Moderna’s FDA review reversal, and Yangzijiang Maritime’s proposed buyback. Back home, the STI reopens with CapitaLand Investment up while OCBC, DFI Retail and Hongkong Land lag - is Singapore ready to gallop into the Year of the Horse? Hear about Berkshire Hathaway, Apple, Amazon, Bank of America, New York Times, Domino’s Pizza, Chevron, Warner Bros Discovery, Netflix, Paramount, Nvidia, Meta, Broadcom, Palo Alto Networks, Moderna, Yangzijiang Maritime, CapitaLand Investment, OCBC, DFI Retail, Hongkong Land.See omnystudio.com/listener for privacy information.

The Food and Drug Administration agreed to begin a review of biotech company Moderna's application to make a new seasonal flu shot available. The decision comes after the FDA initially refused to review the company's application. It's a back and forth that reveals increased turmoil within the agency. WSJ's Liz Essley Whyte takes us inside the FDA's unexpected reversals and explores what's next for the mRNA flu vaccine. Jessica Mendoza hosts.  Further Listening: - The FDA Commissioner on Vaccines and Public Trust - Breakfast Battle: The Cereal Industry vs MAHA Sign up for WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

Something strange is happening in the culture and the headlines are only telling part of the story. From rising violence tied to gender confusion to major pharmaceutical companies losing ground and questions about what is really in our food supply, the pieces are starting to connect. I walk through why these issues are surfacing at the same time and what it reveals about the deeper battle shaping our future. By the end you will see why discernment matters more right now than outrage and how to stand steady while the narrative keeps shifting.   Podcast Episode 2034: Gender Confusion Violence Pattern, Moderna Stock DROPS + Our Food is POISON?! | don't miss this! Listen to more episodes of the Lance Wallnau Show at lancewallnau.com/podcast

In our news wrap Wednesday, the National Institutes of Health Director Dr. Jay Bhattacharya will serve as acting head of the CDC, the FDA reversed its decision to consider whether to approve a new mRNA flu shot from Moderna and billionaire Les Wexner told lawmakers he was "duped by a world-class con-man" as he faced questions about his association with Jeffrey Epstein. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

Rescue teams are searching for missing skiers caught in an avalanche near Lake Tahoe amidst a winter storm. After a setback, authorities continue to canvass neighborhoods for clues in the disappearance of Nancy Guthrie. We'll tell you about another set of deadly US strikes on suspected drug-smuggling vessels. The FDA has reversed course and agreed to review a major drugmaker's flu vaccine. Plus, a software giant says it's on track to invest billions to help low incomes countries gain access to AI. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Plus: U.S. industrial production rose in January. What Berkshire Hathaway bought and sold during Warren Buffett's last quarter as CEO. And Mikaela Shiffrin wins the gold in the women's slalom. Alex Ossola hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Learn more about your ad choices. Visit megaphone.fm/adchoices

Follow-ups: Checking in on Polymarket @2:51 News: V-day scams @8:20 El Paso @10:59 James Talerico @16:14 Politics: Epstein file searches @19:58 Pam Bondi Trump Repeals Key Greenhouse Gas Finding @25:24 TN House passes bill @29:19 MAHA: how to navigate elections @31:04 RFK & Kid Rock workout vid @33:34 Health/Medicine/Science: Latest Quackwatch @36:26 The organization Protect Our Care released a new report @42:35 That announcement comes hot on the heels of this revelation: @43:17 Trump official overruled FDA scientists to reject Moderna's flu shot @44:45 AMA and the Vaccine Integrity Project in Minnesota announced partnering @46:07 Final Stories: What percentage of Americans think Noah was married to Joan of Arc? @47:23

Marley Kayden and Sam Vadas turn their attention to headlines in Big Tech and beyond for their final takeaways. Among the unsung stories: crude oil's climb on geopolitical tensions and the FDA readying to review Moderna's (MRNA) flu vaccine. ======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

The Fed Minutes from their January meeting were released today and we've got news about any rate reduction.  We'll share there tonight first. This is the Business News Headlines for Wednesday the 18th of February, thanks for listening. . In other news, Marc Zuckerberg was in court today and we'll share why. Moderna says the FDA will now consider its new flu vaccine. Hold on, we've got another FDA story for you. The White House feud with the Fed just got hotter. Door Dash reported big revenue but, there is a but.  We'll check the numbers from The Wall Street Report and Shark Tank's Kevin O'Leary posts up a warning for the Trump Administration and we'll share what he wrote on X.  Let's go! Thanks for listening! The award winning Insight on Business the News Hour with Michael Libbie is the only weekday business news podcast in the Midwest. The national, regional and some local business news along with long-form business interviews can be heard Monday - Friday. You can subscribe on  PlayerFM, Podbean, iTunes, Spotify, Stitcher or TuneIn Radio. And you can catch The Business News Hour Week in Review each Sunday Noon Central on News/Talk 1540 KXEL. The Business News Hour is a production of Insight Advertising, Marketing & Communications. You can follow us on Twitter @IoB_NewsHour...and on Threads @Insight_On_Business.

──────────────────────────────────── 00:00:51:15 — Directed Energy Weapons Move From Theory to BattlefieldAutonomous killer systems and microwave weapons are described as transitioning from speculation into active military doctrine. ──────────────────────────────────── 00:07:44:24 — Intelligence Agencies Downplayed Directed Energy CapabilitiesInternal awareness of microwave weapon effects is contrasted with public minimization of their existence. ──────────────────────────────────── 00:14:59:19 — Hypersonic Missiles Undermine “Golden Dome” DefenseAdvanced missile systems are cited as rendering proposed U.S. missile shields technologically and financially unrealistic. ──────────────────────────────────── 00:21:12:01 — Federal Agents Escalate Use of Crowd-Control WeaponsTear gas, flash bangs, and rubber bullets are reportedly deployed broadly against protesters and bystanders. ──────────────────────────────────── 00:29:13:09 — Body Cam Footage Captures Aggressive Use-of-Force DirectiveA supervisor's recorded comments raise concerns about normalization of escalatory force tactics. ──────────────────────────────────── 00:35:48:25 — Federal Immunity Shields Officers From AccountabilityBroad immunity claims collide with court findings noting repeated excessive-force violations. ──────────────────────────────────── 01:04:52:09 — FDA Blocks New mRNA Flu ShotRegulators halt advancement of a Moderna flu vaccine, breaking with expectations of streamlined approval. ──────────────────────────────────── 01:18:50:21 — Vaccines Framed as National Security InfrastructureGlobal health leaders argue vaccine production should operate as centralized state security architecture. ──────────────────────────────────── 01:23:54:27 — Pandemic Policies Normalize Permanent Emergency PowersMandates, liability shields, and censorship are portrayed as embedded tools of governance beyond crisis conditions. ──────────────────────────────────── 01:24:17:13 — Legislative Push to End Vaccine Manufacturer ImmunityNew legislation challenges longstanding liability protections for pharmaceutical companies. ──────────────────────────────────── 01:43:14:10 — Third-Term Discussion Challenges Constitutional LimitsPublic talk of bypassing the 22nd Amendment is framed as normalization of executive permanence. ──────────────────────────────────── 01:55:48:12 — Convicted Elites Rebrand Through Alternative MediaDisgraced figures leverage online platforms to rebuild public narratives and pressure for clemency. ──────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

The U.S. Food and Drug Administration announced recently that it will not review Moderna's mRNA flu vaccine, despite late-stage trials showing it was safe and effective. The rejection has many in and outside the industry concerned about the Trump administration's approach to vaccine development and recommendations. Amna Nawaz discussed more with Michael Osterholm. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

──────────────────────────────────── 00:00:51:15 — Directed Energy Weapons Move From Theory to BattlefieldAutonomous killer systems and microwave weapons are described as transitioning from speculation into active military doctrine. ──────────────────────────────────── 00:07:44:24 — Intelligence Agencies Downplayed Directed Energy CapabilitiesInternal awareness of microwave weapon effects is contrasted with public minimization of their existence. ──────────────────────────────────── 00:14:59:19 — Hypersonic Missiles Undermine “Golden Dome” DefenseAdvanced missile systems are cited as rendering proposed U.S. missile shields technologically and financially unrealistic. ──────────────────────────────────── 00:21:12:01 — Federal Agents Escalate Use of Crowd-Control WeaponsTear gas, flash bangs, and rubber bullets are reportedly deployed broadly against protesters and bystanders. ──────────────────────────────────── 00:29:13:09 — Body Cam Footage Captures Aggressive Use-of-Force DirectiveA supervisor's recorded comments raise concerns about normalization of escalatory force tactics. ──────────────────────────────────── 00:35:48:25 — Federal Immunity Shields Officers From AccountabilityBroad immunity claims collide with court findings noting repeated excessive-force violations. ──────────────────────────────────── 01:04:52:09 — FDA Blocks New mRNA Flu ShotRegulators halt advancement of a Moderna flu vaccine, breaking with expectations of streamlined approval. ──────────────────────────────────── 01:18:50:21 — Vaccines Framed as National Security InfrastructureGlobal health leaders argue vaccine production should operate as centralized state security architecture. ──────────────────────────────────── 01:23:54:27 — Pandemic Policies Normalize Permanent Emergency PowersMandates, liability shields, and censorship are portrayed as embedded tools of governance beyond crisis conditions. ──────────────────────────────────── 01:24:17:13 — Legislative Push to End Vaccine Manufacturer ImmunityNew legislation challenges longstanding liability protections for pharmaceutical companies. ──────────────────────────────────── 01:43:14:10 — Third-Term Discussion Challenges Constitutional LimitsPublic talk of bypassing the 22nd Amendment is framed as normalization of executive permanence. ──────────────────────────────────── 01:55:48:12 — Convicted Elites Rebrand Through Alternative MediaDisgraced figures leverage online platforms to rebuild public narratives and pressure for clemency. ──────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code KNIGHT Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-showOr you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

As targeted protein degradation gains momentum, oral selective estrogen receptor degraders are emerging as one of its most advanced proving grounds. On the latest BioCentury This Week podcast, BioCentury's Lauren Martz assesses how the oral SERD landscape is evolving.Washington Editor Steve Usdin then discusses setbacks at FDA for an orphan therapy from Disc Medicine and a vaccine from Moderna, and why he is calling on life sciences industry leaders to publicly demand the dismissal of Vinay Prasad, FDA's CSO, CMO, and director of CBER.View full story: https://www.biocentury.com/article/658455#TargetedProteinDegradation #OralSERDs #OncologyDrugDevelopment #FDASetbacks #CBER00:00 - Introduction03:12 - Oral SERD Spotlight11:40 - Setbacks at FDA15:12 - Disc Medicine CRLTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events and decisions in the industry that are shaping the path forward for drug development and patient care.The U.S. Food and Drug Administration (FDA), an agency often at the center of pharmaceutical innovation and scrutiny, has recently made several noteworthy decisions. These decisions not only point to the ongoing regulatory challenges but also highlight scientific advancements within the field.One of the key updates involves the FDA's decision to reject Disc's drug bitopertin, which was intended for the treatment of erythropoietic protoporphyria, a rare blood disease. Despite receiving a national priority voucher for expedited review, the FDA ultimately concluded that the clinical data did not sufficiently support regulatory approval. This decision underscores the FDA's commitment to maintaining rigorous standards even when expedited reviews are in play, emphasizing the necessity of robust clinical evidence for approval.Adding complexity to this situation is the internal dynamics within the FDA itself. Richard Pazdur, a long-standing official at the agency, recently stepped down, revealing disagreements with Commissioner Marty Makary over reducing the number of clinical trials required for new drug applications. Pazdur's departure after an influential 26-year tenure highlights ongoing debates within regulatory bodies on how to balance innovative approval pathways with ensuring safety and efficacy data.In another notable development, Moderna faced setbacks with its mRNA-1010 flu vaccine as the FDA declined to review it. This decision leaves American consumers without access to potentially more effective mRNA-based flu vaccines—a technology embraced by other countries for influenza treatment. This situation points to possible missed opportunities in leveraging cutting-edge vaccine technologies domestically, showcasing both the promise and regulatory complexities surrounding mRNA technology.These regulatory challenges unfold amid leadership changes and strategic shifts within health agencies. For instance, Jim O'Neill's departure from his role as acting director of the Centers for Disease Control and Prevention following Susan Monarez's abrupt ouster illustrates how leadership turbulence can impact policy consistency and strategic direction, potentially affecting how new health initiatives are prioritized and implemented.Meanwhile, companies like Vertex and CRISPR Therapeutics are ambitiously advancing gene therapy solutions such as Casgevy, signaling a broader trend towards personalized medicine and advanced biotechnological approaches. These efforts promise transformative impacts on patient care and reflect an industry-wide move towards precision medicine.Eli Lilly's substantial investment in orforglipron stock ahead of its anticipated approval further indicates confidence in their product pipeline amidst growing competition from Novo Nordisk's Wegovy pill abroad. This competitive landscape highlights increasing interest and investment in innovative treatments for metabolic diseases.Overall, these developments illustrate a dynamic interplay between scientific innovation, regulatory scrutiny, and strategic corporate maneuvers that shape healthcare's future. As companies push technological boundaries, regulators face ongoing challenges in adapting frameworks that ensure patient safety while fostering innovation. The outcomes of these processes will significantly influence not only patient access to cutting-edge therapies but also set precedents for future drug development and approval pathways. As these trends unfold, stakeholders across the industry must remain agile, informed, and collaborative to navigate this evolving landscape effectively.Looking back at 2025, it was a tSupport the show

TODAY ON THE ROBERT SCOTT BELL SHOW: MAHA Boosts GOP Momentum, Dr. Stephen Sanders, Whole Mens Health, FDA Blocks Moderna Jab, Dr. Robert Thompson, Mary Kay Stenger, Mineral Medicine Breakthrough, Alfalfa, Medical Freedom Act, and MORE! https://robertscottbell.com/maha-boosts-gop-momentum-dr-sanders-mens-health-fda-blocks-moderna-dr-robert-thompson-aurora-health-mary-kay-stenger-mineral-medicine-breakthrough-alfalfa-medical-freedom-act-and-more/ Purpose and Character The use of copyrighted material on the website is for non-commercial, educational purposes, and is intended to provide benefit to the public through information, critique, teaching, scholarship, or research. Nature of Copyrighted Material Weensure that the copyrighted material used is for supplementary and illustrative purposes and that it contributes significantly to the user's understanding of the content in a non-detrimental way to the commercial value of the original content. Amount and Substantiality Our website uses only the necessary amount of copyrighted material to achieve the intended purpose and does not substitute for the original market of the copyrighted works. Effect on Market Value The use of copyrighted material on our website does not in any way diminish or affect the market value of the original work. We believe that our use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the U.S. Copyright Law. If you believe that any content on the website violates your copyright, please contact us providing the necessary information, and we will take appropriate action to address your concern.

TWiV explains the observation that filamentous virions act as non-infectious interfering particles to modulate papillomavirus infection, and transmission of monkeypox virus from fire-footed rope squirrels to sooty mangabeys. Hosts: Vincent Racaniello, Alan Dove, Kathy Spindler, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV Positions in Rosenfeld Lab (email) FDA refuses to review Moderna flu mRNA vaccine (CIDRAP) Oz measles vaccine call, too little too late? (dw.com) Defective human papillomavirus interfering virus particles (J Virol) Fire-footed rope squirrel potential MPXV reservoir (Nature) Squirrels could be MPXV reservoir (Nature) Letters read on TWiV 1297 Timestamps by Jolene Ramsey. Thanks! Weekly Picks Brianne – Silo TV series Kathy – Ancient RNA expression profiles from the extinct woolly mammoth and Ancient host-associated microbes obtained from mammoth remains Alan – Ubik, by Philip K. Dick Vincent – Starry Messenger by Neil deGrasse Tyson Listener Pick Beth – Iceland crime fiction authors Yrsa Sigurdardottir and Ragnar Jonasson Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

Técnicamente los ciudadanos de Puerto Rico son ciudadanos norteamericanos pero no tienen derecho a votar por los líderes norteamericanos que toman decisiones por su territorio. Cuando la isla ha sido azotada por algún desastre natural tienen fallas terribles de infrastructura y han quedado prácticamente en el abandono. Puerto Rico es una colonia moderna y hoy en Herejes el podcast de contamos su historia e intentamos entender los eventos históricos que produjeron las circunstancias actuales. 2026 es el año de Herejes en Patreon. Mucho más contenido exclusivo creado por todos los Herejes, Larva, y Caro H Solis. Suscríbete y nos ayudas como de ninguna otra forma https://www.patreon.com/herejeselpodcast Merch https://chunchos.mx/collections/herejes - Ale Durán - https://www.instagram.com/corsario.hereje/ - Vasco - https://instagram.com/vasco.hereje/ - @BobbyHereje - https://www.instagram.com/bobby.hereje Learn more about your ad choices. Visit megaphone.fm/adchoices

We get the latest from the Munich Security Conference, where U.S. Secretary of State Marco Rubio delivered a speech before European leaders. We also look at the reasons behind why the FDA rejected Moderna's new flu vaccine and how that decision could shape future clinical trials. Plus, we'll look at the what happened with U.S Olympic figure skater Illia Malinin, dubbed the "Quad God," on the ice yesterday. Tipped to win the gold, Malinin didn't end up even medaling. Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

In his weekly clinical update, Dr. Griffin and Vincent Racaniello are shocked by recent events, including Dr. Oz's appeal for measles vaccination, Vinjay Prasad's unilateral rejection of Moderna's mRNA influenza vaccine application, and the increasing number of New World screw worm cases, then Dr. Griffin then deep dives into recent statistics on RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, where to find PEMGARDA, how to access and pay for Paxlovid, the number of measles deaths in Mexico, long COVID treatment center, where to go for answers to your long COVID questions, choroid plexus alterations in long COVID association with neuropathologies and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode How Dr. Oz's appeal to get measles vaccine may differ from RFK Jr.'s messaging (ABC News) FDA reverses course, refuses to review Moderna's application for new mRNA flu vaccine (CIDRAP) Hepatitis B Vaccination at Birth: Safety, Effectiveness, and Public Health Benefit (American Academy of Pediatrics: Pediatrics) US Olympic Committee remains 'dialed in' to prevent spread of stomach illness at Winter Games (CNN) Oz promotes measles vaccination (NY Times; USA Today; Fortune) Screw worm in Mexico (Gobierno de Mexico) Mexico reports more human New World screwworm infections (CIDRAP) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Big outbreak, bright lights…Measles Dashboard (South Carolina Department of Public Health) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Measles outbreak poses risk of 'irreversible' brain damage, health officials warn (Fox News) In Mexico, at least 28 have died from measles outbreak that started 2025 (Reuters) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) USrespiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: cliff notes (CDC FluView) Influenza vaccination and the risk of myocardial infarction(BMC Publich Health) OPTION 2: XOFLUZA $50 Cash Pay Option(xofluza) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) USrespiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Long-term impact of nirsevimab on prevention of respiratory syncytial virus infection using a real-world global database (Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Where to get pemgarda (Pemgarda) EUAfor the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Choroid plexus alterations in long COVID and their associations with Alzheimer's disease risks (Alzheimer's & Dementia) Reaching out to US house representative Letters read on TWiV 1296 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Carl Quintanilla, Courtney Reagan, and Michael Santoli capped off a big week of volatility and earnings with a panel of market veterans: Moody's Mark Zandi and former Leuthold Group CIO Jim Paulsen, before a deep-dive into 2 of the morning's biggest reports - Airbnb & Roku, with the CEOs of both companies. Hear how Roku is bullish on AI's opportunity to drive down costs - and why the CEO of Airbnb says his company's built to ride the disruption.  Plus: more on the day's biggest earnings reports - spanning Moderna's big earnings beat driving shares higher, to the tariff headwind slamming Pinterest shares.  Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

It looked like Shopify's stock was headed for a great day when it reported earnings, only for the stock to give up all its gains and then some when management started talking on the conference call. The gang discusses why management's comments had such a profound effect on the stock. Plus, a look at Moderna after the recent FDA approval and stocks on our radar Tyler Crowe, Matt Frankel, and Jon Quast discuss: - The market's sharp reaction to Shopify's earnings - e-commerce in the era of agentic commerce - The FDA's refusal to review Moderna's new flu vaccine - Stocks on our radar Companies discussed: SHOP, AMZN, GOOG, PINS, WMT, MRNA, TREX, CROX, SAFRY Host: Tyler Crowe Guests: Matt Frankel, Jon Quast Engineer: Dan Boyd Disclosure: Advertisements are sponsored content and provided for informational purposes only. The Motley Fool and its affiliates (collectively, “TMF”) do not endorse, recommend, or verify the accuracy or completeness of the statements made within advertisements. TMF is not involved in the offer, sale, or solicitation of any securities advertised herein and makes no representations regarding the suitability, or risks associated with any investment opportunity presented. Investors should conduct their own due diligence and consult with legal, tax, and financial advisors before making any investment decisions. TMF assumes no responsibility for any losses or damages arising from this advertisement. We're committed to transparency: All personal opinions in advertisements from Fools are their own. The product advertised in this episode was loaned to TMF and was returned after a test period or the product advertised in this episode was purchased by TMF. Advertiser has paid for the sponsorship of this episode. Learn more about your ad choices. Visit ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices

(February 12, 2026) Key takeaways from Pam Bondi's House hearing. LAPD on course to put drones in the sky as first responders. Thousands of apartments set to take over empty office buildings with new L.A. ordinance. FDA declines to review Moderna flu vaccine.See omnystudio.com/listener for privacy information.

On the DSR Daily for Wednesday, we discuss the Congressional hearing on immigration oversight, the FDA rejecting a Moderna flu vaccine, growing calls for the resignation of Howard Lutnick, and more.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Howie Kurtz on the latest in the investigation into the kidnapping of Nancy Guthrie, newly released Epstein files showing President Trump reportedly contacted Palm Beach Police to support their investigation into Jeffrey Epstein, and the FDA's refusing to review Moderna's application for a new mRNA flu vaccine. Learn more about your ad choices. Visit podcastchoices.com/adchoices